Skip to main content

Table 3 Comparison of different cohorts of seronegative LETM

From: Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies

PublicationPatients numberAge at LETM onset (range) yearsSex ratioAQP4 AbMOG AbMedian EDSS at nadir (range)Chronic treatmentAt least one relapse afterFollow-up duration, (range)Median EDSS at follow-up (range)
Sepulveda et al. [13]23Median 44.5 (20–77)16 F
7 M
2NA7 (3–9)12/23, 52%6/20, 30%Median 32 months (6–54)2.5 (0–8)
Kitley et al. [15]32 including MS, ADEMMean 37.74 (± 16.07)14 F
18 M
068 (3–8)NA31%Median 25 months (1.9–169.4)EDSS at recovery 3 (3–8)
Huyn et al. [12]42Mean 43.1 (± 9.8)9 F
33 M
003 (3–8.5)NA30, 71%Mean 5.4 ± 2.6 years2.5 (1–6)
Cobo-Calvo et al. [14]56 including MSMedian
39.9 (32.3–58.1)
30 F
16 M
0135.0 (3.5–7.8)19/56, 33.9%16, 28.6%Median 42.2 months (25–79.5)2.5 (1.5–4.8)
This cohort53Median 38 (16–80)28 F
25 M
006 (1–8.5)29/53, 55%12/53, 24.5%Median 3.94 years (1.5–12) mean 4.47 years4 (0–8)
  1. Ab antibody, EDSS Expanded Disability Status Scale, F female, M male, MS multiple sclerosis, ADEM acute disseminated encephalomyelitis